LENZ Therapeutics, Inc.
NASDAQ:LENZBiotechnology
-$0.42 today
- Market cap
- $100.86M
- Beta
- 1.47
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$3.48
Volume 0.62M
Average 0.89M
LENZ Change in Working Capital
Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.
LENZ Therapeutics, Inc.NASDAQ: LENZ
Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026
Change in working capital turns positive
Q1 FY2026 change in working capital was $3.38M, compared with -$2.97M a year earlier. Trailing-twelve-month change in working capital was $9.6M.
Context
- Change in working capital amounted to 17.0% of revenue in FY2025.
- Change in working capital increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly change in working capital holds near $3.38M or moves back toward the trailing-twelve-month quarterly average of $2.4M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Change in Working Capital history
USD · from the cash flow
- Latest · FY2025
- 3.25M USD
- Year-over-year change
- +124.8%
| Period | Period end | Change in Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.25M | +124.8% |
| FY2024 | 2024-12-31 | (13.09M) | -239.1% |
| FY2023 | 2023-12-31 | 9.41M | +230.5% |
| FY2022 | 2022-12-31 | (7.21M) | -188.6% |
| FY2021 | 2021-12-31 | (2.5M) | — |
Change in Working Capital vs competitors
How LENZ compares with its peers on the latest reported figures
- Peers report in different currencies, so change in working capital is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +236.2% is the 3rd highest of 11, against a peer median of -93.4%.
- Change in working capital amounts to 45.7% of revenue for LENZ, versus a peer median of 10.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $194M USD | -3761.0% | — | 101.3% | |
| LTM Mar 2026 | $97.28M USD | +4.6% | — | 49.6% | |
| LTM Jun 2026 | $19.19M USD | +345.9% | -43.8% | 9.2% | |
| LTM Mar 2026 | $9.6M USD | +236.2% | — | 45.7% | |
| FY2025 | €3.4M EUR | -2696.2% | +77.7% | 11.5% | |
| LTM Mar 2026 | $3M USD | -237.1% | — | — | |
| LTM Mar 2026 | $1.92M USD | +1599.1% | +73.4% | — | |
SPRYARS Pharmaceuticals, Inc. | LTM Mar 2026 | $988K USD | -93.2% | +16.2% | 1.0% |
| LTM Mar 2026 | $495.64K USD | +217.7% | — | — | |
| LTM Mar 2026 | $196K USD | -93.7% | -34.7% | — | |
| LTM Mar 2026 | $187K USD | -100.3% | -46.8% | 4.6% | |
| Peer median (excluding LENZ) | — | -93.4% | -9.3% | 10.3% | |
Competitors are the stored peer set for LENZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (70.76M) | (101.05M) | (69.97M) | (49.77M) | (82.13M) |
| Depreciation & Amortization | 734K | 8.35M | 15K | 58K | (3.12M) |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 1.34M | 6.37M | 12.55M |
| Change in Working Capital | (2.5M) | (7.21M) | 9.41M | (13.09M) | 3.25M |
| Accounts Receivables | 0 | 0 | 0 | 0 | (329K) |
| Inventory | 0 | 0 | 0 | 0 | (4.28M) |
| Accounts Payables | 1.83M | 194K | 856K | (4.28M) | (90K) |
| Other Working Capital | (4.32M) | (7.4M) | 8.55M | (8.81M) | 7.95M |
| Other Non-Cash Items | 19.67M | 11.93M | (1.18M) | (2.95M) | 279K |
| Operating Cash Flow | (52.85M) | (87.98M) | (60.38M) | (59.39M) | (69.17M) |
| Capital Expenditures | (5.74M) | (6.59M) | (30K) | (468K) | (827K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (405.52M) | (52.09M) | (241.91M) | (280.8M) |
| Sales of Investments | 0 | 170.25M | 22.5M | 87.9M | 205.96M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (5.74M) | (241.86M) | (29.62M) | (154.48M) | (75.67M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 417.16M | 676K | 203K | 79.51M | 149.75M |
| Common Stock Repurchased | 0 | (79K) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 306K | 0 | (2.48M) | 119.49M | 0 |
| Financing Cash Flow | 417.47M | 597K | 80.7M | 199M | 149.75M |
| Effect of Forex Changes | (1.72M) | 0 | 0 | 0 | 0 |
| Net Change in Cash | 357.16M | (329.25M) | (9.3M) | (14.87M) | 4.91M |
| Free Cash Flow | (58.59M) | (94.57M) | (60.41M) | (59.86M) | (70M) |
LENZ Therapeutics, Inc.
NASDAQ:LENZ
Intrinsic Alpha fair value
Locked
Current Price
$3.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.